PAUL HOGUE: Open Payments
NPI 1659704500 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$872 in 33 payments from 9 companies in 2025. Trend: 2023 $3,909 · 2024 $2,022 · 2025 $872
Food & beverage: $872
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 7 | $244 |
| ABBVIE INC. | 9 | $243 |
| Gilead Sciences, Inc. | 10 | $194 |
| Axsome Therapeutics, Inc. | 2 | $56 |
| Merck Sharp & Dohme LLC | 1 | $35 |
| Exact Sciences Corporation | 1 | $33 |
| Bausch Health US, LLC | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $24 |
| Lilly USA, LLC | 1 | $18 |
Products named: VRAYLAR, Auvelity, DOVATO, PIFELTRO, The Cologuard Plus Collection Kit, RUKOBIA, APRETUDE, WELLBUTRIN.
Industry payments across NY — which companies pay providers there.
